After completing 6 rounds of docetaxel end of May 2022, I had clean scans including PSMA PET and my PSA was undetectable. As of my most recent tests, end of Feb, my PSA has already begun to rise slightly. I am just below 1.0 as of last week with increases shown 2 weeks in a row. There is also evidence of possibly 3 new sites of metastases from the NM Bone and CT Scans i took 2 weeks ago. I continue to be on Lupron since discovering my condition in late 2021.
My MO is suggesting nest step as Xtandi, or to enroll in a Phase 1/2 trial that would entail Xtandi in combination with EPI-7386 by ESSA Pharma, ClinicalTrials.gov Identifier: NCT05075577. I am told by my MO that it is a choice and I am not at trial is my only hope stage.
I have also inquired about other trials. I am aware of another phase 1 or 1/2 ( I am unsure) trial that I may be eligible for that combines darolutamide with abemaciclib. I am willing to listen to this but the trial may not begin until April, and scares me because of my lack of knowledge.
Does anyone have any thoughts or insight into these trials, or Xtandi on its own vs in combination.
All responses are greatly appreciated